Pfizer Inc. vs Merck & Co., Inc.
In their latest fiscal years, Pfizer Inc. reported revenue of $62.58B and Merck & Co., Inc. reported $65.01B — MRK was 1.0× larger by revenue. Net income was $7.77B for PFE and $18.25B for MRK.
| Latest fiscal year | PFE · FY ended Dec 2025 | MRK · FY ended Dec 2025 |
|---|---|---|
| Revenue | $62.58B | $65.01B |
| Revenue growth | −1.6% | +1.3% |
| Net income | $7.77B | $18.25B |
| Net margin | 12.4% | 28.1% |
| Diluted EPS | $1.36 | $7.28 |
| Operating cash flow | $11.70B | $16.47B |
| Total assets | $208.16B | $136.87B |
| Total liabilities | $121.39B | — |
| Shareholders' equity | $86.48B | $52.61B |
| Cash & equivalents | $1.14B | $14.56B |
Revenue over time
Go deeper
Both columns use the same XBRL concepts where possible, but companies may define revenue and other line items differently. Banks, insurers and industrial companies are not directly comparable on margins. Source: SEC EDGAR XBRL company facts. Not investment advice.